OM

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Outset Medical Inc

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
CEO
Employees
313
Headquarters

News

Outset Medical executive sells over $50k in company stock
Jun 14, 2024 20:20pm

https://www.investing.com/news/company-news/outset-medical-executive-sells-over-50k-in-company-stock-93CH-3485613


Source:Investing.com
Outset Medical to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 03, 2024 20:05pm

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 45th annual Healthcare conference on Wednesday, June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
OM Stock Earnings: Outset Medical Misses EPS, Misses Revenue for Q1 2024
May 09, 2024 00:58am

Outset Medical (NASDAQ: OM ) just reported results for the first quarter of 2024. Outset Medical reported earnings per share of -57 cents. This was below the analyst estimate for EPS of -55 cents. The company reported revenue of $28.17 million. This was 7.16% worse than the analyst estimate for revenue of $30.34 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.


Source:InvestorPlace
Outset Medical, Inc. (OM) Q1 2024 Earnings Call Transcript
May 08, 2024 23:44pm

Outset Medical, Inc. (NASDAQ:NASDAQ:OM) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ETCompany ParticipantsJim Mazzola - Head, IRLeslie Trigg -…


Source:Seeking Alpha
Why Outset Medical Shares Are Up Today
May 06, 2024 18:40pm

Outset Medical, Inc. (NASDAQ: OM ) shares are trading higher Monday after the company announced that TabloCart with prefiltration received FDA clearance . The Details: Outset said that it has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States. “With the FDA’s clearance of TabloCart with prefiltration, we have delivered features … Full story available on Benzinga.com


Source:Benzinga
Outset Medical stock rallies 40% on FDA clearance of dialysis device
May 06, 2024 15:33pm

Outset Medical (OM) stock surged 40% on FDA clearance of TabloCart with pre-filtration, an optional accessory for the Tablo Hemodialysis System. Read more here.


Source:Seeking Alpha
FDA clears Outset Medical''s new dialysis system accessory
May 06, 2024 14:37pm

https://www.investing.com/news/company-news/fda-clears-outset-medicals-new-dialysis-system-accessory-93CH-3421283


Source:Investing.com
NanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare movers
May 06, 2024 14:01pm

No summary available.


Source:Seeking Alpha
Outset Medical''s TabloCart with Prefiltration Receives FDA 510(k) Clearance
May 06, 2024 12:00pm

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo Hemodialysis System. Outset has resumed distribution Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Outset Medical to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Apr 19, 2024 12:30pm

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online